BioNTech SE (LTS:0A3M)
$ 112.3 4.95 (4.61%) Market Cap: 26.92 Bil Enterprise Value: 8.65 Bil PE Ratio: 0 PB Ratio: 1.25 GF Score: 63/100

BioNTech SE at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 12:00PM GMT
Release Date Price: $201.5 (+2.81%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Former Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutical

It's Navin Jacob. I'm a senior analyst covering SMID-cap biotech and large-cap pharma here at UBS. I'm happy to have with us BioNTech, our next presentation and Q&A session fireside chat. I will be hosting with Ryan Richardson from BioNTech, who is the Chief Strategy Officer. Ryan, welcome. Hope you're well.

Ryan Richardson
BioNTech SE - Chief Strategy Officer, MD & Member of Management Board

Thanks, Navin. Good to be with you.

Questions & Answers

Navin Cyriac Jacob
UBS Investment Bank, Research Division - Former Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutical

Fantastic. So folks, we're going to have a little fireside chat presentation here with Ryan. And if you have questions, please don't be shy, please e-mail them in -- or rather, not e-mail them in. Just post them on this web chat here at the bottom of your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot